GE HealthCare this week unveiled its new AI Innovation Lab, aimed at accelerating early-stage artificial intelligence (AI) innovations within the company to enhance medical devices and healthcare delivery. According to GE HealthCare, these projects are part of the company’s broader AI and digital strategy, which focuses on integrating AI into medical devices, building AI applications that enhance decision-making across the care journey and various disease states, and using AI to support better outcomes and operational efficiencies system-wide through cloud computing technology.
The company in a statement this week said its investment in cloud technology provides the computing power necessary to drive the development of AI at scale.
“The AI Innovation Lab lifts the curtain on the work we are undertaking at the vanguard of healthcare innovation. At GE HealthCare, we’re not just developing technology—we’re striving to break new ground by exploring novel ways that AI could enable healthcare. For example, through projects like Health Companion, we are evaluating ways to apply agentic AI in order to bring the clinical knowledge and problem-solving insights of a multi-disciplinary medical team to clinicians’ fingertips and help them take action,” said Dr Taha Kass-Hout, GE HealthCare’s Global Chief Science and Technology Officer.
“The pioneering projects we’re showcasing today are just some of the innovations we have underway, enabled by our AI and cloud computing capabilities. We will continue to gather feedback from our customers as we find ways to help them apply AI to their health data and convert information into actionable, care-enhancing strategies,” the CTO added.
The first among the lab’s AI-powered projects is Health Companion, which explores whether an agentic AI approach driven by multiple agents—each an expert in a particular area (i.e., genomics, radiology, pathology, etc.)—could help physicians streamline their clinical decision-making and deliver more personalised care.
The project’s vision is for these agents to collaborate and analyse multimodal data to proactively generate treatment plan recommendations, continuously adapting based on new information, GE HealthCare said.
GE HealthCare is exploring whether multi-agentic AI could understand the difference between an expected symptom as a function of treatment and the same symptom as a signal of disease progression, such as cancer spread, with the goal of alerting the care team as appropriate and suggesting next steps.
Predicting Breast Cancer Recurrence with AI
GE HealthCare is also collaborating with Emory University on a research project to predict the recurrence of triple-negative breast cancer, one of the most aggressive cancer subtypes. The project uses deep learning to analyse multimodal data, including genomics and pathology data, to determine if AI can better predict the likelihood of recurrence and help the care team inform a treatment plan and monitoring schedule.
In another project, GE HealthCare is working on a care companion initiative investigating how generative AI could minimise the effort spent searching through data and seeking best practices.
Enhancing Mammography Screening with Cloud-Based AI
Additionally, in a project aimed at helping radiologists scale mammography screenings, GE HealthCare is developing this cloud-based AI concept to explore how foundation models can assist clinicians in quickly identifying normal breast screening exams, allowing radiologists to focus more on suspicious cases.
AI Tools for Maternal Care
In maternal care, GE HealthCare said it is developing AI-powered tools, including a fetal heart rate interpretation system currently under review by the FDA, designed to assist in monitoring baby health during childbirth.
GE HealthCare says it has been investing in AI for years and has topped an FDA list of AI-enabled device authorisations for three consecutive years, with a total of 80 authorisations.
If this article saved you time or helped you decide better, consider supporting our work.
Support Telecomtalk
